

Analysis of Adverse Event Summary (Safety Analysis Population)

| | Placebo | | Xanomeline Low Dose | | Xanomeline High Dose | |
|--|---------|--------|---------------------|--------|----------------------|--------|
| | n | (%) | n | (%) | n | (%) |
| Participants in population | 86 | | 84 | | 84 | |
| With any adverse event | 69 | (80.2) | 77 | (91.7) | 79 | (94.0) |
| With drug-related adverse event | 44 | (51.2) | 73 | (86.9) | 70 | (83.3) |
| With serious adverse event | 0 | (0.0) | 1 | (1.2) | 2 | (2.4) |
| With serious drug-related adverse event | 0 | (0.0) | 1 | (1.2) | 1 | (1.2) |
| Who died | 2 | (2.3) | 1 | (1.2) | 0 | (0.0) |
| Discontinued due to adverse event | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| Every subject is counted a single time for each applicable row and column. | | | | | | |

Source: ADSL and ADAE datasets